Gelonghui, January 29丨Saisheng Pharmaceutical (300485.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 8,1894 million yuan - 112,6043 million yuan, down 45%-60% from the same period of the previous year; net profit loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 42,616 million yuan - 52,533,600 yuan, profit of 334,400 yuan for the same period last year; basic earnings per share were 0.15 yuan/share - 0.25 yuan/share.

The company expects net profit attributable to shareholders of listed companies to decrease by 45%-60% in 2023 compared to the same period last year. The main reasons for the year-on-year decline in annual performance are:

1. During the reporting period, the profit and loss from changes in the fair value of financial assets confirmed by the company in accordance with the new financial instrument standards and investment income of joint ventures decreased compared to the previous period. The financial assets invested by the company were mainly biomedicine, medical devices, etc. related to the company's main business, and health professional investment funds. Among them, biomedicine, medical devices, and fair value change income confirmed by companies related to the company's main business in accordance with the new financial instrument guidelines was about 90 to 10 million yuan, a decrease of about 20% from the same period last year. The investment income of the joint venture was about 40 to 50 million yuan, down about 30% from the same period last year.

2. The company expects net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss in 2023: -52.6533,600 yuan to -42,621,000 yuan. Due to a decrease in sales volume and unit prices of the company's main products compared to the same period last year, the fixed costs of unit cost sharing (expenses such as depreciation of fixed assets) increased, leading to a decrease in gross margin. On the other hand, the holding subsidiaries within the scope of the merger have not achieved large-scale sales and are all in a non-profit state, which in turn affects net profit after deducting non-recurring profit and loss after deducting the consolidated statements. At the same time, the company continues to invest in R&D projects, with annual R&D expenses of about 80 million yuan.

The company's total non-recurring profit and loss is estimated to be approximately RMB 170 million in 2023.